Astragalosides inhibit proliferation of fibroblast‐like synoviocytes in experimental arthritis by modulating LncRNA S56464.1/miR‐152‐3p/Wnt1 signaling axis

Author:

Cui Xiaoya12,Wang Jing12,Fan Chang12,Jiang Hui134ORCID,Li Weiping3

Affiliation:

1. Clinical Research Experiment Center The First Affiliated Hospital of Anhui University of Chinese Medicine Hefei Anhui China

2. College of Pharmacy Anhui University of Chinese Medicine Hefei Anhui China

3. College of Basic Medical Anhui Medical University Hefei Anhui China

4. Anhui Province Key Laboratory of Modern Chinese Medicine Department of Internal Medicine Application Foundation Research and Development Hefei Anhui China

Abstract

AbstractAimAstragalus membranaceus (Fisch.) Bunge., the dried root of the plant A. membranaceus, is widely used in the treatment of rheumatoid arthritis (RA) in many Chinese herbal remedies. Astragalosides (AST) is the primary medicinal ingredient of A. membranaceus and has a therapeutic effect on RA, but the specific mechanism of this effect has yet to be elucidated.MethodsIn this study, MTT and flow cytometry were used to determine the effects of AST on fibroblast‐like synoviocyte (FLS) proliferation and cell cycle progression. Additionally, real‐time quantitative polymerase chain reaction and Western blotting were used to determine the effects of AST on the LncRNA S56464.1/miR‐152‐3p/Wnt1 signaling axis and on critical genes that are essential to the Wnt pathway.ResultsThe data showed that after the administration of AST, FLS proliferation and LncRNA S56464.1, β‐catenin, C‐myc, Cyclin D1, and p‐GSK‐3β(Ser9)/GSK‐3β expression were significantly reduced, and miR‐152 and SFRP4 expression was notably increased.ConclusionThese results suggest that AST can inhibit FLS proliferation by modulating the LncRNA S56464.1/miR‐152‐3p/Wnt1 signaling axis and that AST may be a potential therapeutic drug for RA.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Rheumatology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3